文献综述(Review)

分化型甲状腺癌患者促甲状腺激素抑制治疗中骨代谢变化的研究现状

Published at: 2017年第26卷第5期

贾浩 1 , 刘晓莉 1 , 孙辉 1
1 吉林大学中日联谊医院 甲状腺外科/吉林省外科转化医学重点实验室,吉林 长春 130033
通讯作者 辉 孙 Email: sunhui1229@163.com
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2017.05.017
基金:
吉林省科学技术厅青年科研基金资助项目 20150520149JH

摘要

促甲状腺激素(TSH)抑制治疗是否会对骨密度造成影响,导致部分分化型甲状腺癌(DTC)患者出现骨质疏松症状?尚存争议。笔者从基础实验与临床研究的角度,综述DTC的TSH抑制治疗中骨代谢变化的研究现状。


Research status of bone metabolism changes in patients with differentiated thyroid carcinoma during thyroid-stimulating hormone suppression therapy

Abstract

Whether thyroid-stimulating hormone (TSH) suppression therapy may change bone mineral density and cause osteoporosis signs in some patients with differentiated thyroid carcinoma (DTC) remains controversial. Here, the authors present the current research progress of DTC TSH suppression therapy associated changes in bone metabolism from the viewpoints of both experimental and clinical studies.


comments powered by Disqus

全文

引用

引用本文: 浩 贾, 晓莉 刘, 辉 孙. 分化型甲状腺癌患者促甲状腺激素抑制治疗中骨代谢变化的研究现状[J]. 中国普通外科杂志, 2017, 26(5): 643-647.
Cite this article as: JIA Hao, LIU Xiaoli, SUN Hui . Research status of bone metabolism changes in patients with differentiated thyroid carcinoma during thyroid-stimulating hormone suppression therapy[J]. Chin J Gen Surg, 2017, 26(5): 643-647.